Pay in 4 interest-free payments of $6.70 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
In pharmaceutical M&A, FTO concerns can be as value-destructive as ownership defects or validity problems in the targets own portfolio
These changes have implications for cardiovascular risk assessment
*Correspondence: Juan Huang, [email protected] These authors have contributed equally to this work and share first authorship Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers
Acknowledgements The authors thank Yale Liver Center Morphology Core/Molecular Core Facilities for the support of confocal microscopy, image processing, and biological assays
Mert I, Cetinkaya A, Gurler M, Turel CA, Celik H, Torun IE, Turel I (2022) Anti-inflammatory potential of liraglutide, a glucagon-like peptide-1 receptor agonist, in rats with peripheral acute inflammation
"GLP-1 receptor agonism results in reduction in hepatic ethanol metabolism." npj Metabolic Health and Disease , September 18, 2025
